The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model

This publication has 13 references indexed in Scilit:

• Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy
  Gene Therapy, 2000
• Gene therapy of metastatic colon carcinoma: Regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase
  Cancer Gene Therapy, 2000
• Enzyme/Prodrug Therapy for Head and Neck Cancer Using a Catalytically Superior Cytosine Deaminase
  Human Gene Therapy, 1999
• Regional ‘pro-drug’ gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma
  Gene Therapy, 1998
• Regional Delivery of an Adenovirus Vector Containing the Escherichia coli Cytosine Deaminase Gene to Provide Local Activation of 5-Fluorocytosine to Suppress the Growth of Colon Carcinoma Metastatic to Liver
  Human Gene Therapy, 1996
• In VivoAdenovirus-Mediated Gene Transfer of theEscherichia coliCytosine Deaminase Gene to Human Colon Carcinoma-Derived Tumors Induces Chemosensitivity to 5-Fluorocytosine
  Human Gene Therapy, 1995
• Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system.
  Proceedings of the National Academy of Sciences, 1992
• Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis
  Cancer and Metastasis Reviews, 1991
• Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora
  Antimicrobial Agents and Chemotherapy, 1986
• Evidence for Conversion of 5-Fluorocytosine to 5-Fluorouracil in Humans: Possible Factor in 5-Fluorocytosine Clinical Toxicity
  Antimicrobial Agents and Chemotherapy, 1978